Mark Yan

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Five-Year Outcomes of the POLARIX Study Vergelijking van Pola-R-CHP and R-CHOP in Patiënten met Diffuse Large B-Cell Lymphoma.

Polatuzumab vedotin bij onbehandeld DLBCL: POLARIX fase III